Tot Biopharm receives China regulatory approval for a bevacizumab biosimilar and Fujifilm moves forward with plans for a Suzhou Innovation and Collaboration Center.
An industrialized center northwest of Shanghai, China, was the source of a few items of biosimilars news this week.
Tot Biopharm
Suzhou, China-based Tot Biopharm said it has been granted regulatory approval for a bevacizumab biosimilar (Pusintin) by China’s National Medical Products Administration.
Pusintin (TAB008; injectable) is now approved for the treatment of patients with advanced metastatic or recurrent nonsquamous non–small cell lung cancer and metastatic colorectal cancer.
Bevacizumab reduces tumor-supporting blood vessels by targeting vascular endothelial growth factor. Tot Pharma cited pharmaceutical studies and nonclinical and clinical studies demonstrating that Pusintin is equivalent to the reference product, Avastin.
In China, bevacizumab is also approved for treatment of glioblastoma multiforme, hepatocellular carcinoma, ovarian cancer, and cervical cancer. Tot Pharma has commercial-scale manufacturing operations in Suzhou Industrial Park.
Fujifilm Innovation Center
With the growth of biosimilar markets and the demand for more affordable drugs, the market for cell culture development services is growing in China. Biosimilars are made from living organisms, and cell cultures are necessary for development of these therapeutics.
Fujifilm Irvine Scientific, of Santa Ana, California, said it will establish an Innovation and Collaboration Center in Suzhou New District where employees can design upstream cell culture processes for customers’ biomanufacturing needs.
“In the past decade, the world has seen rapid growth in China’s biopharmaceutical, vaccine, cell and gene therapy markets. The speed of approval of biosimilar drugs and investment by the government to make more affordable drugs available to its people is accelerating that growth,” the company said in a statement. Fujifilm said the market for cell culture media is anticipated to grow at an annual rate of 20%.
“The Innovation and Collaboration Center will incorporate advanced cell culture automation and analysis into process and media development to enable highly accurate evaluation and identification of optimal upstream cell culture processes,” Fujifilm said.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.